Radioembolization of hepatic lesions from a radiobiology and dosimetric perspective, Front Oncol, vol.4, p.210, 2014. ,
,
, Australia: Sirtex Medical Limited, New South Wales, 2017.
Clinical implications of the body surface area method versus partition model dosimetry for yttrium-90 radioembolization using resin microspheres: a technical review, Ann Nucl Med, vol.25, pp.455-461, 2011. ,
Limitations of body surface area-based activity calculation for radioembolization of hepatic metastases in colorectal cancer, J Vasc Interv Radiol, vol.25, pp.1085-1093, 2014. ,
Radioembolization dosimetry: the road ahead, Cardiovasc Intervent Radiol, vol.38, pp.261-269, 2015. ,
Radiodosimetric estimates for radioembolic therapy of liver tumors: challenges and opportunities, J Nucl Med, vol.53, pp.509-511, 2012. ,
, Comparison between optimal-activity calculations based on 99m Tc-MAA and 90 Ymicrosphere dosimetry. In scatterplot on left, dashed line stands for linear regression. In Bland-Altman diagram on right, solid line indicates mean difference and dashed lines 95% limits of agreement
Radioembolization for the treatment of liver tumors: general principles, Am J Clin Oncol, vol.35, pp.91-99, 2012. ,
MIRD pamphlet no. 17: the dosimetry of nonuniform activity distributions-radionuclide S values at the voxel level. Medical Internal Radiation Dose Committee, J Nucl Med, vol.40, pp.11-36, 1999. ,
Evaluation of tumor response after locoregional therapies in hepatocellular carcinoma: are response evaluation criteria in solid tumors reliable?, Cancer, vol.115, pp.616-623, 2009. ,
Patient selection and activity planning guide for selective internal radiotherapy with yttrium-90 resin microspheres, Int J Radiat Oncol Biol Phys, vol.82, pp.401-407, 2012. ,
Imaging of hepatocellular carcinoma after treatment with yttrium-90 microspheres, AJR, vol.188, pp.768-775, 2007. ,
Efficacy and toxicity related to treatment of hepatocellular carcinoma with 90 Y-SIR spheres: radiobiologic considerations, J Nucl Med, vol.51, pp.1377-1385, 2010. ,
Origin, dosimetric effect and clinical limitations of the semi-empirical body surface area method for radioembolisation using yttrium-90 resin microspheres, J Med Imaging Radiat Oncol, vol.60, pp.382-385, 2016. ,
Intrahepatic activity distribution in radioembolisation with yttrium-90-labeled resin microspheres using the body surface area method: a less than perfect model, J Vasc Interv Radiol, vol.26, pp.1615-1621, 2015. ,
Recommendations for radioembolisation after liver surgery using yttrium-90 resin microspheres based on a survey of an international expert panel, Eur Radiol, vol.27, pp.4923-4930, 2017. ,
Clinical feasibility of fast 3-dimensional dosimetry of the liver for treatment planning of hepatocellular carcinoma with 90 Y-microspheres, J Nucl Med, vol.52, pp.1930-1937, 2011. ,
Three-dimensional personalized Monte Carlo dosimetry in 90 Y resin microspheres therapy of hepatic metastases: nontumoral liver and lungs radiation protection considerations and treatment planning optimization, J Nucl Med, vol.55, pp.405-413, 2014. ,
Post-radioembolization yttrium-90 PET/CT: part 2-dose-response and tumor predictive dosimetry for resin microspheres, EJNMMI Res, vol.3, p.57, 2013. ,
PET/MRI of hepatic 90 Y microsphere deposition determines individual tumor response, Cardiovasc Intervent Radiol, vol.39, pp.855-864, 2016. ,
Dose distribution following selective internal radiation therapy, Int J Radiat Oncol Biol Phys, vol.21, pp.463-467, 1991. ,
Analysis of the distribution of intraarterial microspheres in human liver following hepatic yttrium-90 microsphere therapy, Phys Med Biol, vol.45, pp.1023-1033, 2000. ,
Pathologic response and microdosimetry of 90 Y microspheres in man: review of four explanted whole livers, Int J Radiat Oncol Biol Phys, vol.60, pp.1552-1563, 2004. ,
Absorbed dose to lesion and clinical outcome after liver radioembolization with 90 Y microspheres: a case report of PET-based dosimetry, Ann Nucl Med, vol.27, pp.676-680, 2013. ,
Quantitative comparison of yttrium-90 ( 90 Y)-microspheres and technetium-99m ( 99m Tc)-macroaggregated albumin SPECT images for planning 90 Y therapy of liver cancer, Technol Cancer Res Treat, vol.9, pp.253-262, 2010. ,
99m Tc macroaggregated albumin poorly predicts the intrahepatic distribution of 90 Y resin microspheres in hepatic radioembolization, J Nucl Med, vol.54, pp.1294-1301, 2013. ,
Radioembolization of hepatocarcinoma with 90-Y glass microspheres: development of an individualized treatment planning strategy based on dosimetry and radiobiology, Eur J Nucl Med Mol Imaging, vol.42, pp.1718-1738, 2015. ,
,
, J Nucl Med
Alina-Diana Ilonca, Boris Outcome Body-Surface-Area Model to Predict Delivered Dose and Radioembolization ,
, Information about reproducing figures, tables, or other portions of this article can be found online at